midazolam has been researched along with cholest-5-ene-3,4-diol in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Doroshyenko, O; Frank, D; Fuhr, U; Jetter, A; Lütjohann, D; Tomalik-Scharte, D | 1 |
| Andersson, TB; Bäckström, T; Bertilsson, L; Björkhem-Bergman, L; Bredberg, E; Diczfalusy, U; Nylén, H; Rönquist-Nii, Y | 1 |
| Cho, JY; Choi, MH; Jang, IJ; Lim, KS; Shin, KH; Yu, KS | 1 |
| Feng, H; Gu, Z; Han Hsu, H; Li, K; Shu, P; Wang, Y; Wu, X; Zhang, L; Zhao, S | 1 |
| Boulton, DW; Goodenough, A; Jemal, M; Kasichayanula, S; LaCreta, F; Lee, M; Luo, WL; Rodrigues, AD; Yang, Z | 1 |
| Beaton, MD; Choi, YH; Dresser, GK; Gryn, SE; Kim, RB; Tirona, RG; Woolsey, SJ | 1 |
| Mangold, JB; Rebello, S; Wu, F | 1 |
| Lin, YS; Mao, J; Martin, I; McLeod, J; Nolan, G; van Horn, R; Vourvahis, M | 1 |
| Chen, Y; Dean, B; Fan, P; Hop, CECA; Ismaili, MHA; Mao, J; Wang, J; Wong, S; Wright, M | 1 |
| Chun, DY; Dutreix, C; Einolf, HJ; Gu, H; He, H; Ouatas, T; Rebello, S; Wang, L | 1 |
| Hasegawa, M; Tahara, H; Watanabe, M | 1 |
| Krishna, G; LoRusso, PM; Ogasawara, K; Olszanski, AJ; Palmisano, M; Rixe, O; Xu, C; Yin, J | 1 |
| Andersson, S; Andersson, TB; Artursson, P; Åsberg, A; Christensen, H; Eide Kvitne, K; Hertel, JK; Hjelmesæth, J; Hole, K; Jansson-Löfmark, R; Johnson, LK; Karlsson, C; Krogstad, V; Molden, E; Robertsen, I; Sandbu, R; Skovlund, E; Wegler, C; Wollmann, BM | 1 |
| Fallon, JK; Jackson, KD; Lee, J; Smith, PC | 1 |
1 review(s) available for midazolam and cholest-5-ene-3,4-diol
| Article | Year |
|---|---|
Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.
Topics: Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Discovery; Drug Interactions; Humans; Hydrocortisone; Hydroxycholesterols; Liver; Midazolam; Models, Biological | 2017 |
4 trial(s) available for midazolam and cholest-5-ene-3,4-diol
| Article | Year |
|---|---|
Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.
Topics: Adult; Biomarkers; Cholesterol; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Female; Humans; Hydrocortisone; Hydroxycholesterols; Male; Metabolic Clearance Rate; Midazolam; Rifampin | 2013 |
Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance.
Topics: Adult; Biomarkers; Cortisone; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Induction; Gas Chromatography-Mass Spectrometry; Humans; Hydrocortisone; Hydroxycholesterols; Ketoconazole; Liver; Male; Metabolomics; Midazolam; Pharmacogenetics; Rifampin; Young Adult | 2013 |
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
Topics: Adolescent; Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Hydroxycholesterols; Injections, Intravenous; Ketoconazole; Limit of Detection; Midazolam; Middle Aged; Rifampin; Saliva; Substrate Specificity; Time Factors; Tissue Distribution; Young Adult | 2014 |
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Male; Metoprolol; Midazolam; Middle Aged; Neoplasms; Omeprazole; Protein Kinase Inhibitors; Pyrrolidines; Sulfonamides | 2020 |
9 other study(ies) available for midazolam and cholest-5-ene-3,4-diol
| Article | Year |
|---|---|
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?
Topics: Administration, Oral; Adult; Benzilates; Cholesterol; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; HIV Protease Inhibitors; HIV Seropositivity; Humans; Hydroxycholesterols; Infusions, Intravenous; Lopinavir; Male; Midazolam; Middle Aged; Phenotype; Pyrimidinones; Ritonavir | 2009 |
4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.
Topics: Administration, Oral; Animals; Biomarkers; Biotransformation; Cholesterol; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Drug Evaluation, Preclinical; Enzyme Induction; Female; Hydroxycholesterols; Macaca fascicularis; Male; Midazolam; Rifampin; Substrate Specificity; Tandem Mass Spectrometry | 2014 |
Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
Topics: Administration, Oral; Adult; Biomarkers; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Healthy Volunteers; Humans; Hydrocortisone; Hydroxycholesterols; Linear Models; Male; Metabolic Clearance Rate; Midazolam; Polymorphism, Single Nucleotide | 2016 |
Compelling Relationship of CYP3A Induction to Levels of the Putative Biomarker 4β-Hydroxycholesterol and Changes in Midazolam Exposure.
Topics: Biomarkers; Cytochrome P-450 CYP3A; Hydroxycholesterols; Midazolam | 2016 |
Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound.
Topics: Administration, Oral; Animals; Computer Simulation; Cytochrome P-450 CYP3A; Drug Discovery; Drug Interactions; Enzyme Induction; Humans; Hydrocortisone; Hydroxycholesterols; Liver; Macaca fascicularis; Midazolam; Models, Biological; Pharmacokinetics; Rifampin; RNA, Messenger | 2017 |
Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Topics: Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Ketoconazole; Male; Midazolam; Middle Aged; Models, Biological; Rifampin; Staurosporine; Young Adult | 2018 |
A comparative study for detecting CYP3A induction by CYP3A probe drugs and endogenous markers in cynomolgus monkeys.
Topics: Alprazolam; Animals; Area Under Curve; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Drug Interactions; Hydrocortisone; Hydroxycholesterols; Macaca fascicularis; Male; Midazolam; Rifampin; Triazolam | 2019 |
Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.
Topics: Biomarkers; Body Weight; Cytochrome P-450 CYP3A; Humans; Hydroxycholesterols; Liver; Midazolam | 2022 |
Formation of CYP3A-specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β-hydroxycholesterol/cholesterol ratio.
Topics: Biomarkers; Cholesterol; Cytochrome P-450 CYP3A; Humans; Infant; Liver; Midazolam | 2023 |